What is Lantheus Holdings's neuraceq — revenue?

Lantheus Holdings (LNTH) reported neuraceq — revenue of $39.62M in Q2 2026.

What does neuraceq — revenue mean?

This metric represents the total gross revenue generated from the sale or licensing of the Neuraceq diagnostic product, excluding any taxes collected from customers. It serves as a key indicator of market adoption and commercial performance for this specific radiopharmaceutical diagnostic agent within the company's oncology portfolio. Tracking this revenue stream allows investors to evaluate the growth trajectory and competitive positioning of the product in the diagnostic imaging market.

Lantheus Holdings (LNTH) Neuraceq — Revenue

Screener

Other product segments

Oncology

$240.37M—

PYLARIFY

$240.37M-4.1%

Cardiology

$88.28M—

Definity

$88.28M+5.2%

Neurology

$39.62M—

Strategic Partnerships And Other

$19.92M+71.9%

Licenseand Royalty Revenues

$11.25M+222%

SPECT Business

$0—

Similar metrics at other companies

HRO

HROWOther Revenues — Revenue

$73K-15.1%

ORCLCloud Revenues — Revenue

$9.91B+47.1%

ORCLSoftware Revenues — Revenue

$6.82B-2.1%

OWLPerformance revenues — Revenue

$6.07M-3.9%

EAT

EATFranchise revenues — Revenue

$14.7M+21.5%

CNKOther Revenues — Revenue

$113.1M+18.2%

Other financials

Income statement

See full

Revenue$388.2M+2.7%

Gross profit$241.9M+0.4%

Operating income$100.2M+13.9%

Net income$75.0M-4.7%

EPS (diluted)$1.11-0.9%

Balance sheet

See full

Cash & equivalents$595.0M-14.7%

Total debt$626.8M+1.5%

Total equity$1.3B+12.4%

Total assets$2.4B+14.1%

Cash flow

See full

Operating cash flow$92.2M+5.9%

CapEx$2.3M-70.7%

Free cash flow$89.9M+13.5%

Valuation

See full

Market cap$6.63B+84.6%

Enterprise value$6.66B+89.7%

P/E24.1×+11.4×

P/S4.3×+1.9×

Profitability

See full

Gross margin60.1%-3.6pp

Operating margin19.4%-9.4pp

Net margin17.7%-0.9pp

FCF margin24.9%-6.6pp

Returns & leverage

See full

Return on equity22.2%-3.6pp

Debt / equity0.5×-0.1×

Current ratio3.1×-1.2×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Lantheus Holdings’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 8:01 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001193125-26-336795

(in thousands)	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
PYLARIFY	$240,366	$250,642	$481,290	$508,296
Total oncology	240,366	250,642	481,290	508,296
Neuraceq	39,616	—	75,055	—
Total neurology	39,616	—	75,055	—
DEFINITY	88,279	83,939	172,906	163,150
Total cardiology	88,279	83,939	172,906	163,150
Strategic partnerships and other	19,919	11,590	36,262	22,337
SPECT	—	31,874	—	57,026

Item 1. Financial Statements

FAQ

What is Lantheus Holdings's neuraceq — revenue?: Lantheus Holdings (LNTH) reported neuraceq — revenue of $39.62M in Q2 2026.
What does neuraceq — revenue mean?: This metric represents the total gross revenue generated from the sale or licensing of the Neuraceq diagnostic product, excluding any taxes collected from customers. It serves as a key indicator of market adoption and commercial performance for this specific radiopharmaceutical diagnostic agent within the company's oncology portfolio. Tracking this revenue stream allows investors to evaluate the growth trajectory and competitive positioning of the product in the diagnostic imaging market.